AstraZeneca PLC $AZN Position Lessened by Anchor Capital Advisors LLC

Anchor Capital Advisors LLC decreased its stake in AstraZeneca PLC (NASDAQ:AZN) by 26.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 116,464 shares of the company’s stock after selling 42,644 shares during the period. Anchor Capital Advisors LLC’s holdings in AstraZeneca were worth $8,139,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Brighton Jones LLC raised its stake in AstraZeneca by 93.2% during the 4th quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after acquiring an additional 2,789 shares in the last quarter. Bank of New York Mellon Corp raised its stake in AstraZeneca by 7.5% during the 1st quarter. Bank of New York Mellon Corp now owns 994,084 shares of the company’s stock valued at $73,065,000 after acquiring an additional 69,557 shares in the last quarter. Penserra Capital Management LLC raised its stake in AstraZeneca by 7.6% during the 1st quarter. Penserra Capital Management LLC now owns 3,183 shares of the company’s stock valued at $233,000 after acquiring an additional 226 shares in the last quarter. TD Private Client Wealth LLC raised its stake in AstraZeneca by 11.7% during the 1st quarter. TD Private Client Wealth LLC now owns 18,767 shares of the company’s stock valued at $1,379,000 after acquiring an additional 1,959 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC raised its stake in AstraZeneca by 213.9% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 15,484 shares of the company’s stock valued at $1,138,000 after acquiring an additional 10,551 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Down 1.1%

Shares of AZN stock opened at $81.15 on Thursday. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $86.57. The stock has a market cap of $251.68 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 1.52 and a beta of 0.36. The business’s fifty day moving average is $81.24 and its 200-day moving average is $75.32. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86.

Analyst Ratings Changes

AZN has been the topic of several recent analyst reports. Berenberg Bank set a $97.00 target price on AstraZeneca in a research note on Wednesday, July 9th. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Thursday, October 16th. Jefferies Financial Group started coverage on AstraZeneca in a research note on Monday, October 27th. They set a “buy” rating on the stock. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.